|Healthcare Review: Progenics, Rockwell Medical, Valeant Pharmaceuticals, Oculus Innovative Sciences, Galena Biopharma|
|By Staff and Wire Reports|
|Tuesday, 07 January 2014 18:42|
Progenics ($PGNX) rallies on above average volume.SA contributor Gotham City Capital says the company should report positive top-line results from a Phase 2 study of PSMA ADC (chemotherapy cohort) at ASCO's Genitourinary Cancers Symposium Meeting this month."Rarely do companies release bad or mediocre data at these types of conferences," the author says.
Rockwell Medical ($RMTI) is having a strong session. Helping the cause may be the announcement that a Triferic study (PRIME) was selected as best abstract submitted to the 34th Annual Dialysis Conference. In PRIME, Triferic (when regularly administered) lowered ESA usage "while maintaining iron balance and maximizing iron delivery."RMTI hopes that between PRIME and the CRUISE trials, there is enough evidence to show that Triferic can "establish a new paradigm in iron therapy treatment for hemodialysis patients."
Valeant Pharmaceuticals ($VRX) is surging after this morning's financial guidance conference call. The company's financial forecast was in-line with estimates but investors seem pleased with some of the commentary on the call, including CEO Michael Pearson's contention that the company is aiming to become one of the top five pharmaceutical companies on the planet (by market cap) in the next two years."Unless you aim high, you don’t achieve high,” Pearson is quoted as saying, and although he added that he "can't say at this time" exactly how VRX will reach the lofty goal, the implication is that acquisitions will be the catalyst.
Oculus Innovative Sciences ($OCLS) enjoys a positive session after announcing the introduction of two new wound care products. Long story short: Microcyn Wound & Skin Spray HydroGel is now available in a three-ounce spray bottle and Microcyn Wound & Skin Care with preservatives is available in a new multi-use two-ounce bottle.
Galena Biopharma ($GALE) is up 5% after the company has enrolled the first patient in a Phase 2 study of its FBP vaccine GALE-301 in HLA-A2 positive patients. The immunotherapy is intended to "prevent recurrences in high-risk, endometrial and ovarian cancer patients rendered disease-free after completing standard of care therapy."